Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalizing Heart Failure Treatment With Genomics
NCT07490067Phase 4Recruiting
- Sponsor
- University of Michigan
- Start
- Dec 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of metoprolol in heart failure with reduced ejection fraction (HFrEF), sponsored by University of Michigan. Planned start Dec 2026; status: recruiting.
02
Drugs
metoprolol
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07490067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07490067.